ExCell: Stem Cells Therapy for Corneal Blindness
Study Details
Study Description
Brief Summary
This is a investigative initiated, comparative pilot clinical trial to ascertain the safety of application of ex-vivo cultivated limbal stem cells in human eyes for treating different superficial corneal pathologies. Pre-clinical work in murine models have already demonstrated efficacy of this technique in curing murine corneal pathologies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
In this prospective interventional study patients with superficial corneal pathologies like scars, ulcers and burns will undergo a surgical procedure. Limbal ring from a cadaveric donor tissue, which is therapeutically accepted and serologically tested, is collected. This tissue will then be cultivated in the stem cell biology laboratory using standardized culture technique. Briefly the limbal tissue will be cut up into small pieces and digested overnight using an enzyme (Collagenase L). The cells obtained from the digest will be cultured on a petri-dish using 2% serum and growth factors. The cultured cells will be passaged three times to remove all epithelial cells from the culture. In the second procedure, the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 5x10^3 cells/uL diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma. A soft bandage contact lens will be placed over the cornea at the end of the procedure. The patient will receive topical antibiotic and steroid eye drops in the post-operative period. Periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography will be done at day 1, day 7, day 45 and day 90.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Standard Surgical therapy Includes the control group that fulfills the inclusion criteria |
|
| Active Comparator: Ex-vivo cultivated limbal stem cell pool 0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement. |
Biological: Ex-vivo cultivated limbal stem cell pool
0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
|
Outcome Measures
Primary Outcome Measures
- Ocular or systemic adverse effects [until 3months after surgery]
Secondary Outcome Measures
- Visual improvement after treatment. [until 3months after surgery]
Checking for the improvement in visual acuity that will be calculated using LogMAR chart (where 20/20 vision is normal).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male and Female participants who are aged between 18-60 years.
-
Patients who are having with unilateral blindness due to superficial (defined as involving the anterior 200 microns of the corneal stroma on ASOCT imaging) corneal wounds, ulcers, burns and scars.
-
Eyes with otherwise normal.
Exclusion Criteria:
-
Active infection, proven by microbiology.
-
Unknown etiology, post-herpetic eye disease or eyes with active intra-ocular inflammation.
-
Children (<18 years of age).
-
Inability/refusal to give written informed consent or to undergo any of the anterior segment imaging tests.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | LV Prasad Eye Institute | Hyderabad | Telangana | India | 500034 |
Sponsors and Collaborators
- L.V. Prasad Eye Institute
Investigators
- Principal Investigator: Sayan Basu, MBBS, MS, LV Prasad Eye Institiute
- Principal Investigator: Vivek Singh, MSc PhD, LV Prasad Eye Institiute
Study Documents (Full-Text)
More Information
Publications
None provided.- LVPEI-2014-1 Version 1 15Jan14